



## **VPDiagnostics Announces the New Release of Plaque Analysis Software: MRI-PlaqueView 2.0**

April 16, 2010

VPDiagnostics, Inc., a Washington state company specializing in image processing software for analyzing vascular disease, announces release of its lead product, MRI-PlaqueView 2.0. MRI-PlaqueView enables researchers and clinicians to efficiently interpret magnetic resonance imaging (MRI) studies of carotid artery atherosclerosis. The software has advanced tools to highlight plaque features, including semi-automatic plaque delineation and characterization, and to generate concise reports. MRI-PlaqueView can assist clinicians in making management decisions based upon existing scientific literature. MRI-PlaqueView has received FDA 510 (k) clearance.

“MRI-PlaqueView is based on 15 years of research and extensive scientific validation, it provides an efficient analysis tool that allows the user to quickly identify maximum vessel wall thickness, characterize plaque, as well as measure stenosis. These capabilities can be harnessed to help physicians improve patient care, and facilitate research for medical device and pharmaceutical research. ” said Bill Kerwin Ph.D., Vice President of Research and Development, VPDiagnostics, Inc.

MRI-PlaqueView is available with several options packages, ranging from simple burden analysis to semi-automatic plaque segmentation; packages can be tailored to meet the needs and budgets for a wide range of customers. Licenses can be purchased on a per-use basis which requires smaller up-front payments, or MRI-PlaqueView can be purchased with no usage restrictions. MRI-PlaqueView is available directly from VPDiagnostics, Inc.

VPDiagnostics is also leading an NIH-sponsored multi-center prospective clinical trial to evaluate a new diagnostic utility for use with MRI-PlaqueView that will enable the prediction of future risk of stroke and related neurological complications based on plaque characteristics (<http://clinicaltrials.gov/ct2/show/NCT00860184>). The trial will support an FDA submission to establish the first-of-its-kind diagnostic risk predictor based on carotid plaque analysis. VPDiagnostics is actively recruiting clinical sites and research partners for this clinical trial.

VPDiagnostics will be exhibiting at the International Society of Magnetic Resonance in Medicine (ISMRM) 2010 annual meeting to be held from May 1-7 in Stockholm, Sweden.

About VPDiagnostics, Inc. ( [www.vpdiagnostics.com](http://www.vpdiagnostics.com) )

VPDiagnostics, Inc. develops evidence-based imaging solutions to non-invasively diagnose high-risk atherosclerotic plaque before rupture and to enable effective stroke preventive treatments.

VPDiagnostics, Inc. has acquired exclusive commercial rights to the atherosclerotic plaque analysis technologies developed at the Vascular Imaging Laboratory (VIL) at the University of Washington and is establishing research partnerships with other world-class research institutions.

Contact:

VPDiagnostics, Inc.

[www.vpdiagnostics.com](http://www.vpdiagnostics.com)



**vpdiagnostics**

Mike Hartmann

[info@vpdiagnostics.com](mailto:info@vpdiagnostics.com)

206-428-6160.